[Posttransplant diabetes. Metabolic consequences of posttransplant immunosuppressive treatment].
Posttransplant diabetes (PTDM) is persistent hyperglycemia following organ transplantation and is a serious and frequent complication. PTDM increases the risk of graft failure and cardiovascular disease. The most important factor is the posttransplant immunosuppressive treatment. PTDM develops when insulin resistance is not compensated by secretory hyperinsulinemia. New immunosuppressive regimes seem promising in reducing PTDM. Guidelines recommend pre-transplantation OGTT, early diagnose of PTDM and individualized immunosuppressive treatment. Antidiabetic treatment should be initiated early.
Christiansen
Erik
E
Medicinsk Afdeling, Endokrinologisk Funktion, Roskilde Sygehus, DK-4000 Roskilde. rserch@ra.dk
D048909:Diabetes Complications / Q000209:etiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016377:Organ Transplantation / Q000009:adverse effects*; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D007004:Hypoglycemic Agents; D007166:Immunosuppressive Agents